Trial Profile
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis; Encephalitis virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms PRTBEIS
- Sponsors Baxter Vaccines
- 13 Jun 2011 New trial record